The phase 2 AUGMENT-101 study demonstrates that revumenib, a selective menin inhibitor, induces meaningful remissions and enables stem cell transplantation in heavily pretreated, older patients with relapsed or refractory NPM1-mutated AML, addressing a critical unmet need.